bookmark

Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients with Active Ankylosing Spondylitis: Results from an Adaptive Seamless Phase II/III Trial - Arthritis & Rheumatology

https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.43238?af=R

Description

In this trial, Ivarmacitinib 4 mg significantly improved the signs and symptoms of AS at week 12 compared to placebo. These findings support ivarmacitinib 4 mg as a new treatment option for active AS. To read the full article, choose Open Athens “Institutional Login” and search for “Midlands Partnership”.

Preview

Users

Comments and Reviewsshow / hide

Please log in to take part in the discussion (add own reviews or comments).

BibSonomy